Paul Burke - Aion Therapeutic Pres Pharmaceuticals

All Insiders . USA . 
Stock . Aion Therapeutic . Stakeholders . Insider . Paul Burke
ANTCF Stock  USD 0  0.01  65.83%   

Insider

Paul Burke is Pres Pharmaceuticals of Aion Therapeutic
Phone416 460 3000
Webhttps://www.aiontherapeutic.com

Aion Therapeutic Management Efficiency

The company has return on total asset (ROA) of (0.9607) % which means that it has lost $0.9607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.1726) %, meaning that it generated substantial loss on money invested by shareholders. Aion Therapeutic's management efficiency ratios could be used to measure how well Aion Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.
Aion Therapeutic has accumulated 643.8 K in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Aion Therapeutic has a current ratio of 0.15, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aion Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Aion Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aion Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aion to invest in growth at high rates of return. When we think about Aion Therapeutic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

David SpenceHLS Therapeutics
55
Anthony ManoukCannara Biotech
N/A
Julia BouvetCannara Biotech
N/A
Zohar KrivorotCannara Biotech
46
Avi KrivorotCannara Biotech
N/A
Alexander WolfeCannara Biotech
N/A
Susan EmblemKnight Therapeutics
N/A
BA BAKnight Therapeutics
53
Jeff MartensKnight Therapeutics
N/A
Leopoldo BosanoKnight Therapeutics
N/A
Sanjiv SharmaHLS Therapeutics
67
David AbitbolCannara Biotech
N/A
Etienne LedouxCannara Biotech
N/A
Brian ShermanCannara Biotech
N/A
France LandryCannara Biotech
N/A
BA LLBHLS Therapeutics
65
Daniela MarinoKnight Therapeutics
N/A
Tim MBAHLS Therapeutics
51
Gilbert GodinHLS Therapeutics
64
Jody EngelKnight Therapeutics
N/A
JD BAHLS Therapeutics
42
Aion Therapeutic Inc., a pharmaceutical company, offer medical cannabis products in Canada. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada. Aion Therapeutic is traded on OTC Exchange in the United States. Aion Therapeutic [ANTCF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity-4.17
Return On Asset-0.96

Aion Therapeutic Leadership Team

Elected by the shareholders, the Aion Therapeutic's board of directors comprises two types of representatives: Aion Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aion. The board's role is to monitor Aion Therapeutic's management team and ensure that shareholders' interests are well served. Aion Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aion Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
Patricia Purdy, Co Sec
Graham Simmonds, COO CEO
FACS FAANS, Medical Director
Paul Burke, Pres Pharmaceuticals

Aion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Aion Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-4.17
Return On Asset-0.96
Current Valuation1.22 M
Shares Outstanding147.3 M
Shares Owned By Insiders17.68 %
Price To Book5.77 X
Gross Profit(1.5 K)
EBITDA(3.68 M)
Net Income(3.82 M)
Cash And Equivalents1.85 K

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Aion Pink Sheet

Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY